Kaken Pharmaceutical Co., Ltd. (headquarters: Bunkyo-ku, Tokyo; president: Shiro Inui) concluded an agreement with Hanmi Pharm. Co., Ltd. (headquarters: Seoul, Korea; president &CEO: Kyung-yoon, Min) on July 30, 2002, under which Hanmi has a right to exclusively distribute in the Korean market Fiblast Spray for the treatment of bed sores and skin ulcers. After obtaining marketing authorization, Hanmi will distribute the product in the market.
Hanmi Pharm. is among the leading pharmaceutical companies manufacturing and marketing an anti-inflammatory enzyme preparation, alimentary products, antibiotics, etc., and ranked 6th by the sales of 2001. The company estimates that patients suffering from burns and bed sores number 240,000 and 180,000, respectively, and expects that the product will be useful for the treatment of these patients. According to the company, the annual Korean market for wound-healing agents is about 50 billion won (5 billion yen), and the company expects that the sales of the product will reach 20 billion won (2 billion yen) per year in the near future.